Virginia Powers, Ph.D.

Many patients who completed the survey felt maintenance therapy would help them buy time.

Expanding surveillance after surgery from chest X-ray to follow-up with PET-CT scan did not improve overall survival (OS), researchers reported during the 2017 ESMO Congress.

Keytruda (pembrolizumab) produced better overall survival (OS) rates than chemotherapy for patients with recurrent, advanced urothelial carcinoma.

Patients with certain types of sarcoma may benefit from PD-1 blockades, according to a recent study.

A recent trial showed that ribociclib had the similar benefits for elderly patients with breast cancer as it did for younger patients.

After results from a phase 3 trial showed that Keytruda improved overall survival, it may become the next standard of care for patients with advanced urothelial carcinoma.

According to results from a recent trial, patients with heavily pretreated lung cancer showed a durable response and clinical benefit with durvalumab.

Icotinib greatly improved intracranial progression-free survival for patients with lung cancer who have brain metastases, according to a recent study.

While Opdivo showed improved overall survival, there may be a survival risk within the first few months of taking it, according to recently presented data.

Early results showed that avelumab may be a promising option for the treatment of patients with advanced lung cancer.

After doing well in a phase 3 trial, Stivarga showed the potential to shift the treatment paradigm for previously treated liver cancer.

Opdivo may be a promising treatment option for patients with squamous cell carcinoma of the anal canal.

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.